

29 June 29 2007
Announcement no. 23

Extraordinary general meeting: election of members of the Board of Directors

The Board of Directors for BioPorto A/S hereby summons an extraordinary general meeting to be convened:

Wednesday, July 18, 2007, 11.00 a.m., at the Company's address, Grusbakken 8, DK-2820 Gentofte,

with the following agenda:

1. Election of members to the Board of Directors.

The Board of Directors proposes that the Board be made up of four members and nominates the following candidates for election: Ejner Bech Jensen (who is running again), as well as Carsten Lønfeldt, Peter Nordkild and Niels Tækker Foged, all three of whom are running for election for the first time.

Access to the general meeting is conditional on the acquisition of a pass no less than three days before the general meeting, i.e. Friday, July 13, 2007, 11.00 a.m. The pass may be ordered by contacting the Company's office in writing as a registered stockholder or on presentation of documentation for the possession of stock in the Company, e.g. a statement of account of a custody account (no more than 8 days' old). Stockholders' advisors, if relevant, must also obtain passes for the general meeting by name and by the same deadline.

From July 10, 2007 onwards, the agenda will be presented for examination by stockholders at the Company's office on every weekday from 10.00 a.m. to 12 noon. The agenda and any material will be sent to anyone who has requested to receive material regarding the general meeting.

To request a pass, please contact:
Christina Tønnesen, Investor Relations
E-mail: ct@bioporto.com

Election of new members to the Board of Directors

As previously announced, the previous chairman of the board for BioPorto A/S, Christian F. Rovsing, stepped down at the Company's ordinary general meeting on March 21, 2007. The remaining members of the Board have subsequently discussed the future make-up of the Board with a view to ensuring the optimal combination of expertise for leading the continued development and growth of the Company.

BioPorto announced a new strategy for the Company in the 2006 Annual Report, primarily focusing on developing, patenting and commercializing the Company's own products, which marked a departure from the Company's previous strategy of acquisition. The new strategy is based on the considerable potential

ascertained for BioPorto's NGAL product portfolio and the Board aims to use the same approach in selecting, developing and patenting other bio-markers for use in routine medical diagnostics at hospitals, which involves a substantial market potential.

The implementation of the new strategy requires a high degree of focus on research and development in the field of diagnostics and an effective sales and marketing strategy. In the spring of 2007, this focus has been intensified with the injection of additional resources and by implementing and planning for the employment of a number of new employees in the organization.

The Board of Directors has used the modified strategic focus as the basis for discussions of the Board's future make-up. Consequently, the Board is of the opinion that the infusion of new, targeted, business and technical expertise is needed, but that a certain degree of continuity is also required from the part of the Board which has helped to articulate the new strategy.

For this reason, the Board of Directors proposes the election of three new members:

Carsten Lønfeldt (60), previous Group Director for Coloplast A/S

Until the end of 2006, Carsten Lønfeldt was the Group Director for Coloplast where he had been involved with management within a number of strategic key areas for twenty years, such as economy and finance, IT, HR, planning, corporate control and investor relations. After retiring from Coloplast, Carsten Lønfeldt has concentrated on his work for various boards and is also a member of the Advisory Board for OMX The Nordic Exchange, Copenhagen, among others. By virtue of his wide-ranging management background and insight into the biotech industry, Carsten Lønfeldt will be able to provide BioPorto with business expertise, which will be valuable to the Company's continued strategic development.

Education:

M. Sc. (Economics), Copenhagen Business School	1972
--	------

Career:

Novo Industri A/S	1972-1973
Teknologisk Institut	1973-1975
Dansk Signal Industri	1975-1979
Norsk Hydro Olie a.s.	1979-1987

Coloplast A/S:

General Manager, group departments (finance, IT, HR, planning, corporate control, investor relations)	1987
CEO and CFO, member of the group management	1993
Retired	2006

Member of the board:

Polaris Management A/S
 Nykredit Invest
 ATP Invest F.M.B.A.
 Kirkbi A/S
 ALK-Abelló A/S
 Investin/Investin Pro
 ByrumLabflex A/S (chairman)
 Deadline Games A/S (chairman)
 Rheoscience A/S
 Gypsum Recycling International A/S (chairman)

Mr. Lønfeldt is also a member of Nykredit's Committee of Stockholders and the Advisory Board of OMX The Nordic Exchange, Copenhagen.

Peter Nordkild (52), Chief Commercial Officer for Pharmexa A/S

Peter Nordkild is the Chief Commercial Officer and a member of the group management for Pharmexa, where he has been responsible for Pharmexa's international sales and marketing since January 1, 2007. Peter Nordkild is a qualified physician and has worked during the course of his career for a number of companies within the medicinal industry, including a number of years for Novo Nordisk and later as Senior Vice President for Commercial Operations at Ferring Pharmaceuticals where his duties included being responsible for establishing new markets and negotiating licensing agreements. Peter Nordkild's unique international experience will be particularly relevant in the continued strategic exploitation of BioPorto's market-related potential.

Education:

Master of Medicine, Copenhagen University	1982
Pharmaceutical Regulatory Affairs, Rutgers University, New Jersey, USA	1987
Marketing principles, Rider College, New Jersey, USA	1988
Advanced Management Program, INSEAD	1998
Finance for Executives, INSEAD	2003

Career:

Novo Nordisk:

Medical Director, Squibb-Novo (US subsidiary)	1887-1988
Director for Business Development, Diabetes Group	1988-1989
Marketing and Medical Director, Medical Systems Division	1989-1992
Marketing Director, Diabetes Care Division	1992-1994
Marketing Director, Diabetes Care Strategy Unit	1994-1996
General Manager, Novo Nordisk Austria	1996-1998

GN Danavox

1999-1999

Herlev and Bispebjerg University Hospitals

1999-2000

Ferring Pharmaceuticals:

Vice President, and subsequently Senior Vice President, Commercial Operations 2000-2003

Niels Tækker Foged (46), Chief Scientific Officer for Visiopharm A/S

For most of his career, Niels Tækker Foged has worked with research and development, both in public-sector research positions and in managerial positions in the biotech industry, most recently as Chief Scientific Officer for Visiopharm A/S. Up to 2006, he was also head of research and development for DAKO Denmark A/S, where one of the areas of focus, like at BioPorto, was the development of antibodies for diagnostics. Niels Tækker Foged is a Doctor of Veterinary Medicine and the author of a number of internationally recognized scientific articles in fields such as microbiology. The combination of Niels Tækker Foged's scientific, market-related and managerial background will be an important asset for BioPorto in the Company's continued focus on the research and development of diagnostic products.

Education:

Chemical engineer, Technical University of Denmark	1985
Graduate diploma in Business Administration (Business Finance)	1989
Doctor of Veterinary Medicine, Royal Veterinary and Agriculture University, Copenhagen	1992

Career:

Statens Veterinære Serumlaboratorium	1985-1990
DAKO A/S, Manager, veterinary microbiology	1991-1992
Center for Clinical & Basic Research , Head of the Basic Research Dept.	1992-1998
Osteopro A/S , Managing Director	1998-2001
Nordic Bioscience A/S , Vice President, Research	2002
DAKO A/S , Director, R&D	2002-2006
Visiopharm A/S , Chief Scientific Officer	2006-

Seppo Mäkinen, Senior Partner, Biofund, who has been a member of BioPorto's Board of Directors since 2004, has decided to resign from the Board of Directors at the time of the extraordinary general meeting. In terms of expertise, Seppo Mäkinen has assisted the Board in its acquisition efforts and, in the light of the revised strategy, he has felt that it was only natural to relinquish his seat on the Board to a new member.

Lars Heslet, Professor, M. D., has chosen to resign from the Board as of June 27, 2007, to focus his efforts in other areas. Lars Heslet has established many good contacts in clinical research circles for the Board, and these contacts have been decisive for the Company's development up to the modification of the strategy.

By adopting the proposal recommended by the Board of Directors, the Board will comprise a total of four members in the future: Ejner Bech Jensen, Director of R&D, Novozymes, who has been a member of the Board since 2005, and the three new members.

The Board intends to elect Carsten Lønfeldt as the new chairman of the board.

Board of Directors

To request a pass, please contact:

Christina Tønnesen, Investor Relations
E-mail: ct@bioporto.com

Additional information:

Please contact Thea Olesen, Managing Director.

BioPorto A/S
Grusbakken 8
DK-2820 Gentofte
Tel.: +45 4529 0029
E-mail: info@bioporto.com